KIT-13

N/A

Report date: 2025/05/23 11:38:48

NME

Base Information

Drug NameKIT-13

Drug Alias NameKIT-13

ClassificationSmall molecules > Lipid

Mechanisms of ActionInterleukin-1 beta inhibitorsMitogen-activated protein kinase; ERK1/ERK2 phosphorylation inducersTranscription factor p65 inhibitors

TargetsInterleukin-1 betaMitogen-activated protein kinase; ERK1/ERK2Transcription factor p65

Therapy Area/IndicationsNerve DegenerationRett Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNeuroCores Inc

China Registration ClassN/A

Develop Information

Active CompaniesNeuroCores Inc

Inactive CompaniesN/A

Active IndicationsNerve DegenerationRett Syndrome

Inactive IndicationsN/A

Other Information

ATC CodeN/A